Merck Jumps Into Lucrative Adjuvant NSCLC Space With Keytruda Data

 
• By Alaric DeArment
  
lung illustration
Merck announced Phase III interim data for Keytruda in adjuvant NSCLC • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category